Patents by Inventor Eugene C. Butcher
Eugene C. Butcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090280113Abstract: Methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (CMKLR1). Methods are also provided for screening for agents that find use in treating demyelinating inflammatory disease in a subject.Type: ApplicationFiled: May 11, 2009Publication date: November 12, 2009Inventors: Kareem Graham, Brian A. Zabel, Eugene C. Butcher
-
Patent number: 7266458Abstract: The involvement of an expression product in a cell in a pathway is determined by genetically modifying the cell, incubating the cell with predetermined factors in induce a physiological state and measuring parameters affected by the pathway. Changes in the levels of the parameters as a result of the presence of the expressed product indicate that the expression product is involved with the pathway.Type: GrantFiled: September 5, 2002Date of Patent: September 4, 2007Assignee: Bioseek, Inc.Inventors: Ivan Plavec, Ellen L. Berg, Eugene C. Butcher
-
Patent number: 6881406Abstract: Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra?, and integrin ?4?7?, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.Type: GrantFiled: April 17, 2001Date of Patent: April 19, 2005Assignees: The Board of Trustees of the Leland Stanford Junior University, Millennium Pharmaceuticals, Inc.Inventors: Eugene C. Butcher, James J. Campbell, Lijun Wu, James B. Rottman
-
Publication number: 20040219592Abstract: Clinical patient tissue samples are classified according to the physiological status of cells present in the sample. In some embodiments of the invention, such cells are classified according to their ability to respond to therapeutic agents and treatments. In other embodiments, the cells or tissue samples are classified according to their status with respect to the activity of pathways of interest. The information thus derived is useful in prognosis and diagnosis, and can further be used develop surrogate markers for disease states, and to investigate the effect of genetic polymorphisms in the responsiveness and state of cells involved in disease.Type: ApplicationFiled: May 27, 2004Publication date: November 4, 2004Applicant: BioSeek, Inc.Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose
-
Publication number: 20040157269Abstract: A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.Type: ApplicationFiled: November 17, 2003Publication date: August 12, 2004Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose
-
Patent number: 6763307Abstract: Clinical patient tissue samples are classified according to the physiological status of cells present in the sample. In some embodiments of the invention, such cells are classified according to their ability to respond to therapeutic agents and treatments. In other embodiments, the cells or tissue samples are classified according to their status with respect to the activity of pathways of interest. The information thus derived is useful in prognosis and diagnosis, and can further be used develop surrogate markers for disease states, and to investigate the effect of genetic polymorphisms in the responsiveness and state of cells involved in disease.Type: GrantFiled: September 13, 2001Date of Patent: July 13, 2004Assignee: BioSeek, Inc.Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose
-
Publication number: 20040063088Abstract: A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.Type: ApplicationFiled: September 11, 2003Publication date: April 1, 2004Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose, Ivan Plavec
-
Patent number: 6692922Abstract: The invention relates to the interaction of MEC with CCR3 and/or CCR10 and to agents (e.g., ligands, antibodies, antagonists, agonists, inhibitors, promoters) which alter said interaction. In one aspect, the invention relates to methods for detecting or identifying an agent (i.e., molecule or compound) which can modulate (inhibit, promote) the binding of MEC to CCR3 and/or CCR10. In another aspect, the invention relates to a method of treating a subject having an inflammatory condition, comprising administering to the subject an effective amount of an agent which modulates the binding of MEC to CCR3 and/or CCR10.Type: GrantFiled: August 15, 2001Date of Patent: February 17, 2004Assignees: The Board of Trustees of the Leland Stanford Junior University, Millennium Pharmaceuticals, Inc.Inventors: Eugene C. Butcher, Eric J. Kunkel, Junliang Pan, Dulce Soler-Ferrán
-
Patent number: 6656695Abstract: A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.Type: GrantFiled: March 6, 2001Date of Patent: December 2, 2003Assignee: Bioseek, Inc.Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose
-
Publication number: 20030138811Abstract: The involvement of an expression product in a cell in a pathway is determined by genetically modifying the cell, incubating the cell with predetermined factors in induce a physiological state and measuring parameters affected by the pathway. Changes in the levels of the parameters as a result of the presence of the expressed product indicate that the expression product is involved with the pathway.Type: ApplicationFiled: September 5, 2002Publication date: July 24, 2003Inventors: Ivan Plavec, Ellen L. Berg, Eugene C. Butcher
-
Publication number: 20030133937Abstract: Methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl Lea and di-sialyl Lea, which are expressed at the surface of cancer cells, function as a binding partner for LEC-CAMs, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that LEC-CAMs, such as ELAM-1, involved in cancer metastasis share a carbohydrate domain common to both sialyl Lea and sialyl Lex. Antibodies, saccharides, glycoconjugates, enzyme inhibitors and other compounds may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.Type: ApplicationFiled: October 10, 2002Publication date: July 17, 2003Applicant: John L. MagnaniInventors: John L. Magnani, Eugene C. Butcher, Ellen L. Berg
-
Publication number: 20030113807Abstract: A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses.Type: ApplicationFiled: March 6, 2001Publication date: June 19, 2003Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose
-
Publication number: 20030017445Abstract: Clinical patient tissue samples are classified according to the physiological status of cells present in the sample. In some embodiments of the invention, such cells are classified according to their ability to respond to therapeutic agents and treatments. In other embodiments, the cells or tissue samples are classified according to their status with respect to the activity of pathways of interest. The information thus derived is useful in prognosis and diagnosis, and can further be used develop surrogate markers for disease states, and to investigate the effect of genetic polymorphisms in the responsiveness and state of cells involved in disease.Type: ApplicationFiled: September 13, 2001Publication date: January 23, 2003Inventors: Ellen L. Berg, Eugene C. Butcher, Jennifer Melrose
-
Patent number: 6465434Abstract: Methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl Lea and di-sialyl Lea, which are expressed at the surface of cancer cells, function as a binding partner for LEC-CAMs, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that LEC-CAMs, such as ELAM-1, involved in cancer metastasis share a carbohydrate domain common to both sialyl Lea and sialyl Lex. Antibodies, saccharides, glycoconjugates, enzyme inhibitors and other compounds may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.Type: GrantFiled: November 23, 1999Date of Patent: October 15, 2002Assignees: Stanford UniversityInventors: John L. Magnani, Eugene C. Butcher, Ellen L. Berg
-
Publication number: 20020137107Abstract: The invention relates to the interaction of MEC with CCR3 and/or CCR10 and to agents (e.g., ligands, antibodies, antagonists, agonists, inhibitors, promoters) which alter said interaction. In one aspect, the invention relates to methods for detecting or identifying an agent (i.e., molecule or compound) which can modulate (inhibit, promote) the binding of MEC to CCR3 and/or CCR10. In another aspect, the invention relates to a method of treating a subject having an inflammatory condition, comprising administering to the subject an effective amount of an agent which modulates the binding of MEC to CCR3 and/or CCR10.Type: ApplicationFiled: August 15, 2001Publication date: September 26, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventors: Eugene C. Butcher, Eric J. Kunkel, Junliang Pan, Dulce Soler-Ferran
-
Patent number: 6391857Abstract: Novel methods and compositions are provided for modulating homing of leukocytes, particularly lympho-cytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1-X[Fuc&agr;1-y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration and for directing molecules to such sites.Type: GrantFiled: November 9, 1994Date of Patent: May 21, 2002Assignees: Stanford UniversityInventors: John L. Magnani, Eugene C. Butcher, Ellen L. Berg
-
Patent number: 6387884Abstract: Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1−X[Fuc&agr;1−y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration.Type: GrantFiled: November 9, 1994Date of Patent: May 14, 2002Assignees: Stanford UniversityInventors: John L. Magnani, Eugene C. Butcher, Ellen L. Berg
-
Publication number: 20020019341Abstract: Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra31 , and integrin &agr;4&bgr;731 , express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity.Type: ApplicationFiled: April 17, 2001Publication date: February 14, 2002Inventors: Eugene C. Butcher, James J. Campbell, Lijun Wu, James B. Rottman
-
Patent number: 6245332Abstract: Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra−, and integrin &agr;4&bgr;7−, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity.Type: GrantFiled: January 15, 1999Date of Patent: June 12, 2001Assignees: The Board of Trustees of the Leland Stanford Junior University, LeukoSite, Inc.Inventors: Eugene C. Butcher, James J. Campbell, Lijun Wu, James B. Rottman
-
Patent number: 6121233Abstract: Methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl Le.sup.a and di-sialyl Le.sup.a, which are expressed at the surface of cancer cells, function as a binding partner for LEC-CAMs, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that LEC-CAMs, such as ELAM-1, involved in cancer metastasis share a carbohydrate domain common to both sialyl Le.sup.a and sialyl Le.sup.x. Antibodies, saccharides, glycoconjugates, enzyme inhibitors and other compounds may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.Type: GrantFiled: May 5, 1994Date of Patent: September 19, 2000Assignee: John L. MagnaniInventors: John L. Magnani, Eugene C. Butcher, Ellen L. Berg